AnGes, Inc.Company Review & Valuation

AJW
Börse Frankfurt

About AnGes, Inc.

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. The company's lead product is HGF Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. It also offers Naglazyme, a dShow more rug for the treatment of mucopolysaccharidosis VI, an intractable disease in Japan. In addition, the company is developing NF?B Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan; and SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases. It also has alliances with Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and co-development agreement with Vasomune Therapeutics for the development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan. Show less

Industry
Biotechnology
HQ Location
Ibaraki, Japan

Stock Price

Price data not available for AnGes, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

back to top